Clinical trials: Tocilizumab
Immune-related Adverse Events, Advanced Solid Tumor
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use.
- Trial name
- NCT04375228
- Testing
- Rituximab, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Hematologic Malignancy, Bone Marrow Transplant
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor…
- Trial name
- NCT04395222
- Testing
- Tocilizumab, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Weill Medical College of Cornell University
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the…
- Conditions
- Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
- Trial name
- EXTEND (NCT02293837)
- Testing
- Tocilizumab (TCZ), Standard of Care
- Where
- 19 sites in United States, Australia
- Volunteers
- 136 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis
This open-label randomized 2arm study will investigate the pharmacokinetics, pharmacodynamics, efficacy and safety of subcutaneously administered tocilizumab in patients with rheumatoid arthritis who have shown an inadequate…
- Trial name
- NCT00965653
- Testing
- folic acid, methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 7 sites in Canada, New Zealand and 1 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Psychotic Disorders
Tocilizumab in Schizophrenia
This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Tocilizumab (Actemra) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia.
- Trial name
- NCT02874573
- Testing
- Tocilizumab, Normal saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brian Miller
Rheumatoid Arthritis
An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis
This observational study evaluates the use and efficacy of intravenous (IV) tocilizumab in routine clinical practice in participants with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01741688
- Testing
- Tocilizumab
- Where
- 4 sites in Peru
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
This 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (MTX) in patients with…
- Trial name
- NCT00106535
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 152 sites in United States, Australia and 14 more
- Volunteers
- 1,196 people
- Sponsor
- Hoffmann-La Roche
Leukemia Acute Myeloid - AML
Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia
This is a phase 1, open label, interventional, single center, in patients with Acute Myeloid Leukemia (AML). This study will investigate dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy.
- Trial name
- TOCIVENA (NCT07392814)
- Testing
- increase dose of tocilizumab
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma (MM), Multiple Myeloma Refractory
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- CORE-MM (NCT07637578)
- Testing
- Elranatamab, Tocilizumab
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Hematopoietic Stem Cell Transplantation
A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
This is a phase II open label trial designed to evaluate the efficacy of Tac/MTX/Toc in preventing graft versus host disease (GVHD).
- Trial name
- NCT02206035
- Testing
- Tacrolimus, Methotrexate, Tocilizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- William R. Drobyski, MD
Rheumatoid Arthritis, Tocilizumab
Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis
Rationale: A wide range of serum trough concentrations is observed in tocilizumab-treated rheumatoid arthritis (RA) patients, while 1 mg/L tocilizumab is sufficient to block systemic interleukin-6 receptor.
- Trial name
- NCT03781310
- Testing
- Tocilizumab
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Covid19 Pneumonia
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation.
- Trial name
- NCT04377750
- Testing
- Tocilizumab
- Where
- 4 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Rheumatoid Arthritis
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
This open-label, single arm, Phase 3b study will evaluate the efficacy of tocilizumab (RoActemra), administered as monotherapy or in combination with methotrexate and/or other DMARDs, in participants with moderate to severe…
- Trial name
- NCT01941940
- Testing
- Tocilizumab, DMARDs
- Where
- 49 sites in Italy
- Volunteers
- 227 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT00721123
- Testing
- Tocilizumab
- Where
- 69 sites in Argentina, Australia and 15 more
- Volunteers
- 538 people
- Sponsor
- Hoffmann-La Roche
Aneurysm, Behcet Syndrome, Vascular Type
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of…
- Trial name
- NCT05845723
- Testing
- tocilizumab, tofacitinib, cyclophosphamide
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Peking Union Medical College Hospital
Rheumatoid Arthritis
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis
This is an open-label, non-interventional study to evaluate efficacy and safety in rheumatoid arthritis participants receiving tocilizumab as per the product label.
- Trial name
- NCT02721004
- Testing
- Tocilizumab
- Where
- Austria
- Volunteers
- 592 people
- Sponsor
- Hoffmann-La Roche
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Nonsmall Cell
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Trial name
- NCT04691817
- Testing
- Atezolizumab, Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Spondylitis, Ankylosing
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in patients with ankylosing spondylitis (AS) who had an inadequate response to previous tumor necrosis…
- Trial name
- NCT01209689
- Testing
- Tocilizumab
- Where
- 140 sites in United States, Australia and 17 more
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488
This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with RA.
- Trial name
- RITACT (NCT01715831)
- Testing
- DMARDs, Tocilizumab
- Where
- 9 sites in Brazil
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche